TriangleIvonescimab (NCT07070466)
Ivonescimab trial for Stomach Cancer Stage IV (NCT07070466). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with HER2-negative adenocarcinoma of the stomach, esophagus, or their junction that is unresectable or metastatic. Prior treatment for stage IV disease is excluded.
The idea: ivonescimab targets PD-1 immune suppression and VEGF blood-vessel signals. It starts alone; FOLFOX chemotherapy joins from cycle two. Intravenous treatment repeats every two weeks for up to two years, if tolerated without progression. Researchers assess six-month progression-free survival and safety.
This phase 2 study plans 40 patients. Samuel Klempner leads at Massachusetts General Hospital in Boston; two US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.